Ask AI
ProCE Banner Activity

ASCENT-04/KEYNOTE-D19: PFS2 With 1L Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC

Conference Coverage
Slideset

In the randomized phase III ASCENT-04 trial, sacituzumab govitecan plus pembrolizumab prolonged PFS2 compared with chemotherapy plus pembrolizumab in patients with PD-L1–positive (CPS ≥10) advanced TNBC despite a high rate of crossover to sacituzumab govitecan monotherapy.

Released: June 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from breast cancer studies at ASCO 2026 and expert guidance to optimize personalized breast cancer care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify breast cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for breast cancer to accelerate their effective incorporation into clinical practice